RB1 variant confirms retinocytoma in 19-year-old

Retinocytoma is the benign-looking cousin of retinoblastoma — and that distinction matters a lot more than it sounds. One is usually indolent. The other is a childhood eye cancer. The problem is that a quiet retinal lesion can sit there for years, looking stable, while the real question stays unresolved: is this just a scarred oddity, or is it an RB1-driven tumor with hereditary implications? A new Ophthalmology Retina case pushes that question into sharper focus by showing molecular confirmation of retinocytoma in a 19-year-old woman with a germline RB1 variant. ### What was the actual case? The patient was a 19-year-old woman from Benin who came in for myopia evaluation. She had no relevant personal or family history on presentation, but she did have a clue buried in childhood care: laser photocoagulation in the right eye at age 10 for an “indeterminate” lesion. On exam, doctors found a pearlescent calcified lesion with adjacent retinal elevation rather than a one-off scar. ### Why wasn’t imaging alone enough? Because retinocytoma can mimic other benign retinal lesions, especially when the tumor is calcified, translucent, partially regressed, or ringed by pigment changes. The classic picture is a gray-translucent mass with calcification and retinal pigment epithelium alteration, but real patients do not always read like a textbook. In this case, multimodal RB1 pathogenic variant. ### What is RB1 doing here? RB1 is the core tumor-suppressor gene in hereditary retinoblastoma biology. When RB1 function is lost, retinal cells can escape normal growth control. Retinocytoma and retinoblastoma are closely linked on that spectrum — basically, they share the same gene story but not always the same clinical behavior. EyeWiki’s summary puts retinocytoma on the benign end of that retinoblastoma pathway, still tied to biallelic RB1 inactivation. ### What was the key molecular finding? The report identified a germline RB1 variant, c.2359C>T. That matters because it moved the diagnosis from “looks like retinocytoma” to “this lesion is molecularly anchored to the retinoblastoma gene.” In plain English, the genetics backed up the eye exam. That is the part residents and general ophthalmologists should care about — the gene result changed the level of certainty, and with it the counseling burden. ### Why does bilateral disease change the stakes? Bilateral or multifocal retinal tumors always raise the hereditary flag. Even when the lesions are benign-appearing, multiple tumors in both eyes suggest a germline predisposition rather than an isolated local event. That is why RB1 testing matters here beyond naming the lesion — it also points toward inherited cancer risk management, not just retinal follow-up. ### Is retinocytoma completely harmless? No — just much less aggressive. Retinocytoma usually has a favorable course, and recent series show malignant transformation is rare, but not impossible. That is why the standard posture is surveillance, not dismissal. A 2025 case series from Institut Curie found no malignant transformation during follow-up in 16 cases, yet still argued for regular follow-up because the risk is real even if uncommon. ### So what should clinicians take from this? If a teenager or young adult has an unusual retinal tumor with calcification, translucency, or multifocality, do not stop at “probably benign.” The catch is that the eye can look quiet while the genetics are loud. Multimodal imaging helps, but genetics can close the loop — and once RB1 is in play, oncology-genetics referral and long-term surveillance stop being optional extras. ### Bottom line This case matters because it turned a plausible diagnosis into a confirmed one. For retinocytoma, that extra certainty is not academic — it changes who needs counseling, who needs follow-up, and how seriously a “stable” retinal lesion should be taken.